GlassScriptPhysician profile
Aundrea L Wallace
NPI 1053930404
$836.37
in general payments reported to CMS, 2019-2025
18 companies · $616 in 2025
The $616 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.57 · 2022: $81.07 · 2023: $127 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $127.45 | 2023 | Nuedexta |
| Novo Nordisk INC | $83.82 | 2025 | Ozempic, Rybelsus, Wegovy |
| Avanir Pharmaceuticals, INC. | $72.29 | 2021-2022 | |
| Pfizer INC. | $64.17 | 2025 | |
| Glaxosmithkline, LLC. | $62.20 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $53.25 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $51.27 | 2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $45.12 | 2025 | |
| Dexcom, INC. | $44.19 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $41.62 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $41.55 | 2025 | Givlaari |
| Xeris Pharmaceuticals, INC. | $32.67 | 2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $25.83 | 2025 | Spravato |
| Vanda Pharmaceuticals INC. | $20.69 | 2025 | Hetlioz, Fanapt |
| Acadia Pharmaceuticals INC | $20.35 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $19.74 | 2025 | |
| Shield Therapeutics INC | $16.40 | 2025 | |
| Axsome Therapeutics, INC. | $13.76 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aundrea Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.